Physician profile
Eric G Sonnenberg
NPI 1619316726
$1,566.64
in general payments reported to CMS, 2019-2025
21 companies · $45.86 in 2025
The $45.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.22 · 2020: $11.18 · 2021: $11.69 · 2022: $77.72 · 2023: $414 · 2024: $957 · 2025: $45.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $251.32 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $205.94 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $172.01 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $139.28 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $133.75 | 2024 | Airsupra, Farxiga |
| Exact Sciences Corporation | $91.50 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $81.34 | 2024-2025 | |
| Pfizer INC. | $75.78 | 2019-2023 | |
| Amgen INC. | $75.24 | 2019-2024 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $52.00 | 2023-2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.28 | 2023-2024 | Jardiance, Synjardy |
| Dynavax Technologies Corporation | $44.77 | 2024 | Heplisav-B |
| Corcept Therapeutics | $25.94 | 2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $25.83 | 2023 | Camzyos |
| Mylan Specialty L.P. | $25.17 | 2024 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.97 | 2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $23.29 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $19.40 | 2024 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $17.23 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $16.49 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sonnenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.